Literature DB >> 20844550

Elevated epidermal ornithine decarboxylase activity suppresses contact hypersensitivity.

Martin P Keough1, Candace S Hayes, Karen DeFeo, Susan K Gilmour.   

Abstract

Previous reports have shown that elevated polyamine biosynthesis is sufficient to promote skin tumorigenesis in susceptible mouse strains. We hypothesized that increased activity of epidermal ornithine decarboxylase (ODC), a key regulatory enzyme in polyamine biosynthesis, may suppress the cutaneous immune response in addition to stimulating proliferation. Using an ODCER transgenic mouse model in which ODC is targeted to the epidermis, we examined the effect of ODC overexpression in keratinocytes on a classic contact hypersensitivity (CHS) response. Compared with normal littermate mice, ODCER transgenic mice showed reduced ear swelling, reduced neutrophil infiltration, and decreased migration of fluorescein isothiocyanate-loaded dendritic cells (DCs) to draining lymph nodes following hapten elicitation of CHS. In addition, elevated epidermal ODC activity suppressed the levels of cytokines keratinocyte-derived chemokine, monocyte chemoattractant protein-1, interleukin-6 (IL-6), and IL-10. Adoptive transfer of lymphocytes from sensitized ODCER transgenic or normal littermate mice to naive ODCER transgenic or wild-type mice indicated that elevated epidermal ODC activity suppresses both the sensitization and elicitation phases of CHS. The specific ODC inhibitor, α-difluoromethylornithine, abrogated all suppressive effects of ODC in CHS reactions. Collectively, these data suggest that the immunosuppression promoted by increased epidermal ODC is mediated by a reduction in cytokine levels, which suppresses DC migration and reduces immune cell infiltration to the site of hapten application.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844550      PMCID: PMC3155882          DOI: 10.1038/jid.2010.263

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  34 in total

1.  Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin.

Authors:  T G O'Brien; L C Megosh; G Gilliard; A P Soler
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

2.  Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B.

Authors:  Michele A Grimbaldeston; Susumu Nakae; Janet Kalesnikoff; Mindy Tsai; Stephen J Galli
Journal:  Nat Immunol       Date:  2007-09-02       Impact factor: 25.606

3.  Enhanced epidermal Langerhans cell migration in IL-10 knockout mice.

Authors:  B Wang; L Zhuang; H Fujisawa; G A Shinder; C Feliciani; G M Shivji; H Suzuki; P Amerio; P Toto; D N Sauder
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

4.  Defective immune response and severe skin damage following UVB irradiation in interleukin-6-deficient mice.

Authors:  N Nishimura; C Tohyama; M Satoh; H Nishimura; V E Reeve
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

5.  Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.

Authors:  Rainer Kunstfeld; Satoshi Hirakawa; Young-Kwon Hong; Vivien Schacht; Bernhard Lange-Asschenfeldt; Paula Velasco; Charles Lin; Edda Fiebiger; Xunbin Wei; Yan Wu; Daniel Hicklin; Peter Bohlen; Michael Detmar
Journal:  Blood       Date:  2004-04-20       Impact factor: 22.113

6.  Epidermal Langerhans cells are not required for UV-induced immunosuppression.

Authors:  Liangchun Wang; Stephen C Jameson; Kristin A Hogquist
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis.

Authors:  Jeremy B Swann; Matthew D Vesely; Anabel Silva; Janelle Sharkey; Shizuo Akira; Robert D Schreiber; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

Review 9.  Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy.

Authors:  A E Pegg
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

10.  Elicitation of delayed allergic skin reactions with haptens; the dependence of elicitation on hapten combination with protein.

Authors:  H N EISEN; L ORRIS; S BELMAN
Journal:  J Exp Med       Date:  1952-05-01       Impact factor: 14.307

View more
  6 in total

1.  Polyamine-stimulation of arsenic-transformed keratinocytes.

Authors:  Eric T Alexander; Kelsey Mariner; Yelizaveta Borodyanskaya; Allyson Minton; Susan K Gilmour
Journal:  Carcinogenesis       Date:  2019-08-22       Impact factor: 4.944

Review 2.  Immune regulation by microbiome metabolites.

Authors:  Chang H Kim
Journal:  Immunology       Date:  2018-04-17       Impact factor: 7.397

3.  Spermine synthase overexpression in vivo does not increase susceptibility to DMBA/TPA skin carcinogenesis or Min-Apc intestinal tumorigenesis.

Authors:  Patricia A Welsh; Suzanne Sass-Kuhn; Chethana Prakashagowda; Diane McCloskey; David Feith
Journal:  Cancer Biol Ther       Date:  2012-04-01       Impact factor: 4.742

Review 4.  Polyamines in cancer: integrating organismal metabolism and antitumour immunity.

Authors:  Cassandra E Holbert; Michael T Cullen; Robert A Casero; Tracy Murray Stewart
Journal:  Nat Rev Cancer       Date:  2022-04-27       Impact factor: 69.800

5.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

6.  Polyamine blockade promotes antitumor immunity.

Authors:  Candace S Hayes; Mark R Burns; Susan K Gilmour
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.